bluebird bio Inc., to spin off its oncology programs to 2seventy bio

This Form 10 reflects bluebird bio’s plans for a tax-free spin-off of its oncology programs and portfolio into 2seventy bio as a publicly traded company. The spin-off is on track to be completed by early November 2021.

bluebird will continue to focus on gene therapies and 2seventy bio will focus on cell therapies, including the anti-BCMA CAR-T therapy Abecma (idecabtagene vicleucel).bluebird will be marketing Zynteglo (betibeglogene autotemcel, beti-cel) in Europe, a gene therapy for transfusion-dependent beta-thalassemia (TDT) and also in development for sickle cell disease (SCD), and also in Europe marketing Skysona (elivaldogene autotemcel, eli-cel) for cerebral adrenoleukodystrophy (CALD) – which is in development in the US as Lenti-D.

2seventy will have not only Abecma on the market but another CAR-T for multiple myeloma, bb21217, in Phase I development with data expected at the American Society of Hematology meeting in December. By the end of the year, 2seventy plans to file investigational new drug applications for two additional CAR-Ts – the CD33-targeting CAR-T therapy DARIC 33 in pediatric acute myeloid leukemia and the CD79a/CD20-targeting CAR-T bbT369 in B-cell non-Hodgkin’s lymphoma.